Story perspectives

Corvus Soquelitinib Breaks Records with Eczema Study Success

1/21/2026

Summary

Story summary

Corvus Pharmaceuticals reached a nine-year high on January 20, 2026, after promising results for its eczema treatment soquelitinib.
An eight-week study showed 75% of participants experienced significant improvement in skin lesions, compared with 20% on placebo.
Oppenheimer analyst Jeff Jones noted that soquelitinib was effective regardless of patient background.
Adam Feuerstein, a biotech columnist, reported on these developments and highlighted their potential impact on drug development and biotechnology.

1 of 1

Story summary

Corvus Pharmaceuticals reached a nine-year high on January 20, 2026, after promising results for its eczema treatment soquelitinib.
An eight-week study showed 75% of participants experienced significant improvement in skin lesions, compared with 20% on placebo.
Oppenheimer analyst Jeff Jones noted that soquelitinib was effective regardless of patient background.
Adam Feuerstein, a biotech columnist, reported on these developments and highlighted their potential impact on drug development and biotechnology.